Integrated BioPharma, Inc. (INBP)
| Market Cap | 6.62M |
| Revenue (ttm) | 62.65M |
| Net Income (ttm) | -116,000 |
| Shares Out | 30.10M |
| EPS (ttm) | -0.00 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 100 |
| Open | 0.220 |
| Previous Close | 0.217 |
| Day's Range | n/a |
| 52-Week Range | 0.170 - 0.380 |
| Beta | 0.52 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About INBP
Integrated BioPharma, Inc., together with its subsidiaries, manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products primarily in the United States and Luxembourg. It operates through Contract Manufacturing and Other Nutraceutical Businesses segments. The Contract Manufacturing segment manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized health-care providers. The Other Nutraceutical Businesses segment distributes healthful nutritional produ... [Read more]
Financial Performance
Financial StatementsNews
Integrated BioPharma Reports Results for its Quarter Ended March 31, 2024
HILLSIDE, NJ / ACCESSWIRE / May 10, 2024 / Integrated BioPharma, Inc. (OTCQX:INBP) (the "Company" or "INBP") reports its financial results for the quarter ended March 31, 2024. Revenue for each of the...
Integrated BioPharma Reports Results for its Quarter Ended December 31, 2023
HILLSIDE, NJ / ACCESSWIRE / February 12, 2024 / Integrated BioPharma, Inc. (OTCQX:INBP) (the "Company" or "INBP") reports its financial results for the quarter ended December 31, 2023. Revenue for the...
Integrated BioPharma Reports Results for its Quarter Ended September 30, 2023
HILLSIDE, NJ / ACCESSWIRE / November 9, 2023 / Integrated BioPharma, Inc. (OTCQX:INBP) (the "Company" or "INBP") reports its financial results for the quarter ended September 30, 2023. Revenue for the...
Integrated BioPharma Reports Results for its Quarter and Fiscal Year Ended June 30, 2023
HILLSIDE, NJ / ACCESSWIRE / September 15, 2023 / Integrated BioPharma, Inc. (OTCQX:INBP) (the "Company" or "INBP") reports its financial results for the quarter and fiscal year ended June 30, 2023. Re...
Integrated BioPharma Reports Results for its Quarter Ended March 31, 2023
HILLSIDE, NJ / ACCESSWIRE / May 11, 2023 / Integrated BioPharma, Inc. (OTCQX:INBP) (the "Company" or "INBP") reports its financial results for the quarter ended March 31, 2023. Revenue for the quarter...
Integrated BioPharma Announces the Sudden Death of Its Executive Chairman and President
HILLSIDE, NJ / ACCESSWIRE / March 21, 2023 / Integrated BioPharma, Inc. (OTCQX:INBP) (the "Company" or "INBP") announced that Edward G. Kay, the Company's Founder, Executive Chairman and President pas...
Integrated BioPharma Reports Results for its Quarter Ended December 31, 2022
HILLSIDE, NJ / ACCESSWIRE / February 10, 2023 / Integrated BioPharma, Inc. (OTCQX:INBP)) (the "Company" or "INBP") reports its financial results for the quarter ended December 31, 2022. Revenue for th...
Integrated BioPharma Reports Results for Its Quarter Ended September 30, 2022
HILLSIDE, NJ / ACCESSWIRE / November 10, 2022 / Integrated BioPharma, Inc. (OTCQX:INBP) (the "Company" or "INBP") reports its financial results for the quarter ended September 30, 2022. Revenue for th...
Integrated BioPharma Reports Results for its Quarter and Fiscal Year Ended June 30, 2022
HILLSIDE, NJ / ACCESSWIRE / September 13, 2022 / Integrated BioPharma, Inc. (OTCQX:INBP) (the "Company" or "INBP") reports its financial results for the quarter and fiscal year ended June 30, 2022. Re...
Integrated BioPharma Announces Change in Directors
HILLSIDE, NJ / ACCESSWIRE / June 21, 2022 / Integrated BioPharma, Inc. (OTCQX:INBP) (the "Company" or "INBP") announced today Mr. Carl DeSantis has resigned as a Class I Director from the Company's Bo...
Integrated BioPharma Reports Results for its Quarter Ended March 31, 2022
HILLSIDE, NJ / ACCESSWIRE / May 12, 2022 / Integrated BioPharma, Inc. (OTCQX:INBP) (the "Company" or "INBP") reports its financial results for the fiscal quarter ended March 31, 2022. Revenue for the ...
Integrated BioPharma Reports Results for its Quarter Ended December 31, 2021
HILLSIDE, NJ / ACCESSWIRE / February 10, 2022 / Integrated BioPharma, Inc. (OTCQX:INBP) (the "Company" or "INBP") reports its financial results for the quarter ended December 31, 2021. Revenue for the...
Integrated BioPharma Reports Results for its Quarter Ended September 30, 2021
HILLSIDE, NJ / ACCESSWIRE / November 10, 2021 / Integrated BioPharma, Inc. (OTCQX:INBP) (the "Company" or "INBP") reports its financial results for the quarter ended September 30, 2021. Revenue for th...
Integrated BioPharma Reports Results for its Quarter and Fiscal Year Ended June 30, 2021
HILLSIDE, NJ / ACCESSWIRE / September 2, 2021 / Integrated BioPharma, Inc. (OTCQX:INBP) (the "Company" or "INBP") reports its financial results for the quarter and fiscal year ended June 30, 2021. Rev...
OTC Markets Group Welcomes Integrated BioPharma, Inc. to OTCQX
NEW YORK, Jan. 22, 2021 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 11,000 U.S. and global securities, today announced Integrated BioPharma, Inc. (OTCQX: IN...